openPR Logo
Press release

New Report Examines the Growth of Generalized Anxiety Disorder (GAD) Market Forecast to 2023

09-06-2017 03:35 PM CET | Health & Medicine

Press release from: Transparency Market Research

New Report Examines the Growth of Generalized Anxiety Disorder

Generalized anxiety disorder is characterized by excessive anxiety and worry about everyday life events with no apparent reason. The patient cannot stop worrying about health, family, money, or work and eventually anxiety dominates the person thinking, that interfere with daily functioning of person. Symptoms of generalized anxiety disorder includes an unrealistic view of problems, muscle tension, headache, sweating, and tiredness. Additionally, rarely GAD occurs alone as it often accompanied by other anxiety disorder, substance abuse, and depression. Number of factors are responsible to develop GAD which includes genetics, brain chemistry, and environmental factors such as trauma and stressful event, family background, or life experiences.

The disorder comes on progressively and can arise across the life cycle, though the risk is highest between childhood and middle age. GAD is diagnosed when a person worries excessively of everyday problems for more than six months and has three or more symptoms. According to Centers for Disease Control and Prevention (CDC), prevalence of anxiety disorder in Europe is over 15 % of total Europe population. In addition, CDC stated that prevalence of disorder is more in women than men. Generally, psychotherapy is preferable to GAD patient before medication which teaches a person different ways of reacting, and thinking in various life situations.

Generalized anxiety disorder market is segmented into therapeutics, and geography. The therapeutics market is segmented into antidepressant, buspirone, and benzodiazepines. Antidepressants further segmented into selective serotonin reuptake inhibitor (SSRI), and serotonin norepinephrine reuptake inhibitor(SNRI). Benzodiazepines includes alprazolam (Niravam, Xanax), chlordiazepoxide (Librium), diazepam (Valium) and lorazepam. However, benzodiazepines can be habit forming hence, generally used for short term basis and consider as a last choice of treatment. Antidepressant are first line therapy for GAD patient hence, hold the largest market share globally.

Geographically, generalized anxiety disorder market segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa, and Rest of the World (RoW). North America dominates the global generalized anxiety market due to increasing incidence of anxiety disorders, and more awareness in people related to anxiety and it is expected to maintain the position during forecast period. However, Asia Pacific market is expected to grow at a faster rate due to changing lifestyle lead to increasing stress, and growing facilities to detect anxiety disorders.

Some of the major driving factors to propel the generalized anxiety disorders market are increasing incidence rate due to more stressful life, Sedentary lifestyle, and presence of strong pipeline. According to National Institute of Mental Health, every year GAD affects minimum 6.8 million adults, or 3.1% of the U.S. population. In the National Comorbidity Survey carried out in 2005, 58% of patients diagnosed with major depression were found to have an anxiety disorder; among these patients, the rate of comorbidity with GAD was 17.2%. However, poor diagnosis rate as no single diagnosis test is available to detect generalized anxiety disorder, affectivity of psychotherapy, and side effects of medications such as habit forming nature, dry mouth, and nausea could restraint the market growth. Focusing on emerging countries such as BRICS countries would create an opportunity for a market players.

Some of the key players of the global generalized anxiety disorder market are Eli Lilly and Company, GlaxoSmithKline Pharmaceuticals Limited, Pfizer, Inc., Abbott Laboratories, Baxter International, Bristol-Myers Squibb, Actavis Pharmaceutical Company, F. Hoffmann-La Roche, Recordati Rare Diseases, Noven Pharmaceuticals, Inc., Sumitomo Dainippon Pharma, and Shionogi and Company.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release New Report Examines the Growth of Generalized Anxiety Disorder (GAD) Market Forecast to 2023 here

News-ID: 701189 • Views:

More Releases from Transparency Market Research

Facial Injectables Market to Surpass US$ 27.0 Billion by 2035 Fueled by Non-surgical Aesthetic Demand and Aging Population
Facial Injectables Market to Surpass US$ 27.0 Billion by 2035 Fueled by Non-surg …
The global facial injectables market was valued at US$ 10.3 Bn in 2024 and is expected to reach US$ 27.0 Bn by 2035, expanding at a CAGR of 9.2% from 2025 to 2035, according to a market intelligence report published by Transparency Market Research Inc. Rising preference for non-invasive aesthetic treatments, aging population, and growing male interest in cosmetic enhancements are key contributors to the rapid market growth. Get Sample PDF
Transplant Diagnostics Market to Surpass US$ 17.2 Bn by 2035 with CAGR of 7.3% Fueled by Organ Transplant Surge and Technological Innovations
Transplant Diagnostics Market to Surpass US$ 17.2 Bn by 2035 with CAGR of 7.3% F …
The global transplant diagnostics market was valued at US$ 7.8 Bn in 2024 and is projected to reach US$ 17.2 Bn by 2035, expanding at a CAGR of 7.3% from 2025 to 2035, according to a comprehensive market study by Transparency Market Research. The surge in organ transplant procedures, growing awareness of organ donation, and rapid technological advancements in molecular diagnostics and genetic testing are major factors accelerating market growth. Get
Coronary Stents Market to Cross US$ 12.8 Bn by 2035 Driven by Minimally Invasive Interventions and Technological Innovation: Transparency Market Research
Coronary Stents Market to Cross US$ 12.8 Bn by 2035 Driven by Minimally Invasive …
The global coronary stents market was valued at US$ 7,222.5 Mn in 2024 and is projected to expand at a CAGR of 5.3% from 2025 to 2035, reaching US$ 12,846.6 Mn by 2035, according to a new market outlook by Transparency Market Research. Market growth is fueled by increasing prevalence of coronary artery disease (CAD), rising preference for minimally invasive procedures, and favorable reimbursement frameworks across key healthcare economies. Get Sample
Smart Insulin Pens & Pumps Market Forecast 2035: Digital Diabetes Management and Personalized Drug Delivery Accelerate Market Expansion | Transparency Market Research, Inc
Smart Insulin Pens & Pumps Market Forecast 2035: Digital Diabetes Management and …
The global Smart Insulin Pens & Pumps Market is poised for significant transformation, driven by rising diabetes prevalence and the pressing demand for personalized, efficient, and user-friendly insulin delivery solutions. Valued at US$ 6.1 Bn in 2024, the market is projected to grow at a CAGR of 8.5% from 2025 to 2035, surpassing US$ 14.6 Bn by the end of 2035. As healthcare increasingly adopts patient-centric approaches and connected medical

All 5 Releases


More Releases for GAD

AMI Healthcare and GAD International Announce Hospital Management Partnership
Boston and Riyadh, Saudi Arabia, Aug 21, 2021 -- Today, AMI Healthcare Group, Inc. (“AMI”) and GAD International company (“GAD”) signed a Memorandum of Understanding to establish a Strategic Partnership for the operation and management of hospitals and healthcare facilities in the Middle East, principally in the Kingdom of Saudi Arabia, the State of Kuwait, the Kingdom of Bahrain and the United Arab Emirates. AMI and GAD will collaborate to
Generalized Anxiety Disorder (GAD) Market to Register Substantial Expansion by 2 …
Generalized anxiety disorder is characterized by excessive anxiety and worry about everyday life events with no apparent reason. The patient cannot stop worrying about health, family, money, or work and eventually anxiety dominates the person thinking, that interfere with daily functioning of person. Symptoms of generalized anxiety disorder includes an unrealistic view of problems, muscle tension, headache, sweating, and tiredness. Additionally, rarely GAD occurs alone as it often
Gad Analyzer, Sensor & Detector Market is Determined to Cross US$ 3 Billion By 2 …
The Global Gad Analyzer, Sensor & Detector Market is expected to exceed more than US$ 3 Billion by 2022 at a CAGR of 4% in the given forecast period. You Can Browse Full Report here: https://www.marketresearchengine.com/gad-analyzer-sensor-and-detector-market The Global Gad Analyzer, Sensor & Detector Market is segmented on the lines of its technology, application and regional. Based on technology type segmentation it covers Electrochemical, Infrared, Metal Oxide Semiconductor (MOS), Catalytic, Zirconia, Photo Ionization
Generalized Anxiety Disorder (GAD) Market Report Forecasts Impressive Growth by …
Generalized anxiety disorder is characterized by excessive anxiety and worry about everyday life events with no apparent reason. The patient cannot stop worrying about health, family, money, or work and eventually anxiety dominates the person thinking, that interfere with daily functioning of person. Symptoms of generalized anxiety disorder includes an unrealistic view of problems, muscle tension, headache, sweating, and tiredness. Additionally, rarely GAD occurs alone as it often
Generalized Anxiety Disorder (GAD) Market 2023 By Top Players
Generalized anxiety disorder is characterized by excessive anxiety and worry about everyday life events with no apparent reason. The patient cannot stop worrying about health, family, money, or work and eventually anxiety dominates the person thinking, that interfere with daily functioning of person. Symptoms of generalized anxiety disorder includes an unrealistic view of problems, muscle tension, headache, sweating, and tiredness. Additionally, rarely GAD occurs alone as it often
Generalized Anxiety Disorder (GAD) Market Research Report by Regional Analysis - …
Generalized anxiety disorder is characterized by excessive anxiety and worry about everyday life events with no apparent reason. The patient cannot stop worrying about health, family, money, or work and eventually anxiety dominates the person thinking, that interfere with daily functioning of person. Symptoms of generalized anxiety disorder includes an unrealistic view of problems, muscle tension, headache, sweating, and tiredness. Additionally, rarely GAD occurs alone as it often accompanied by